Patents Represented by Attorney, Agent or Law Firm The firm of Gordon W. Hueschen
  • Patent number: 6162822
    Abstract: A compound of formula (I) ##STR1## in which: m, and n, which may be identical or different, represent 0 or 1,X and Y, which may be identical or different, represent hydrogen or halogen or alky, trihaloalkyl, alkoxy, hydroxyl, cyano, nitro, amino, alkylamino or dialkylamino,Z represent a linear or branched C.sub.4 to C.sub.12 alkylene chain in which one or more --CH.sub.2 -- are optionally replaced by any one of the following atoms or groups: --NR--, --O--, --S--, --SO--, --SO.sub.2 --, or --CONH--, or by a substituted or unsubstituted heterocylcic,A forms, with two adjacent carbon atoms of the phenyl ring, a phenyl, naphthyl or tetrahydronaphthyl ring or a heterocycle, ##STR2## and medicinal products containing the same are useful as anticancer agent.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: December 19, 2000
    Assignee: Adir et Compagnie
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Ghanem Atassi, Alain Pierre, Laurence Kraus-Berthier, Stephane Leonce
  • Patent number: 6162811
    Abstract: The compounds of formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and A are as defined in the description, their optical isomers and N-oxides, and pharmaceutically acceptable addition salts thereof with an acid or base, and the use thereof as anti-tumor agents.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: December 19, 2000
    Assignee: Adir et Compagnie
    Inventors: Claude Guillonneau, Yves Charton, Emile Bisagni, Ghanem Atassi, Alain Pierre, Nicolas Guilbaud
  • Patent number: 6153638
    Abstract: The invention concerns the use of efaroxan or therapeutically-acceptable salts, in its racemic form or in the form of an optically-active isomer, for treating Huntington's disease.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: November 28, 2000
    Assignee: Pierre Fabre Medicament
    Inventors: Marc Marien, Jean-Claude Martel, Francis Colpaert, Thierry Imbert
  • Patent number: 6153625
    Abstract: A compound selected from those of formula (I): ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be identical or different, represent hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, trihaloalkyl, or any pair may form a heterocycle,R.sub.5 represents hydrogen, alkyl, or arylalkyl,R.sub.6 represents hydrogen, halogen, alkyl, hydroxy, alkoxy, or trihaloalkyl,A, together with the carbons of the phenyl, represents a heterocycle,their isomers and addition pharmaceutically-acceptable acid or base salts thereof, and medicinal products containing the same which are useful in the treatment of pathologies in which 5HT.sub.1B receptors are involved.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: November 28, 2000
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Adrian Newman-Tancredi
  • Patent number: 6147110
    Abstract: Compound of formula (I): ##STR1## wherein: B represents optionally substituted (C.sub.1 -C.sub.6)-alkylene,W represents oxygen or sulphur,R represents hydrogen, hydroxy, R', or OR', R' being as defined in the description,G.sub.1 and G.sub.11 are as defined in the description,G.sub.2 represents a group selected from: ##STR2## wherein R.sub.20, R.sub.21, and R.sub.2 are as defined in the description, and medicinal products containing the same which are useful as melatoninergic ligands.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: November 14, 2000
    Assignee: Adir et Compagnie
    Inventors: Daniel Lesieur, Nicolas Ruiz, Valerie Wallez, Sophie Boye, Caroline Bennejean, Pierre Renard, Philippe Delagrange
  • Patent number: 6143789
    Abstract: Compound of formula (I): ##STR1## wherein: T represents alkylene,A and B together form a naphthalene, dihydronaphthalene, or tetrahydronaphthalene group,R represents hydrogen, hydroxy, R' or OR', R' being as defined in the description,G.sub.1 represents halogen, a radical R.sub.1 or a group --O--CO--R.sub.1, R.sub.1 being as defined in the description,G.sub.2 represents a group selected from: ##STR2## X, R.sub.2 and R.sub.21 being as defined in the description, and medicinal products containing the same which are useful in the treatment of a condition related to the melatoninergic system.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: November 7, 2000
    Assignee: Adir et Compagnie
    Inventors: Fran.cedilla.ois Lefoulon, Luc Demuynck, Daniel Lesieur, Patrick Depreux, Caroline Bennejean, Pierre Renard, Philippe Delagrange
  • Patent number: 6133454
    Abstract: The present invention relates to a process for the industrial synthesis of a substituted perhydroisoindole of formula (I): ##STR1## and of pharmaceutically acceptable salts thereof. The compound of formula (I) and its addition salts have especially valuable pharmacological properties. It is a very powerful secretor of insulin, which makes it useful in the treatment of non-insulin-dependent diabetes.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: October 17, 2000
    Assignee: Adir et Compagnie
    Inventors: Jean-Pierre Lecouve, Claude Fugier, Jean-Claude Souvie
  • Patent number: 6132360
    Abstract: A severed or otherwise interrupted spinal cord or peripheral nerve is provided with magnetic nanoparticles which are absorbed or actively incorporated into the neurons and their axons. The severed or otherwise interrupted nerve or cord is then exposed to an external magnetic field which is moved longitudinally of the severed or otherwise interrupted nerve or spinal cord, thereby stretching the magnetic particle-loaded neurons and their axons along the desired axis for bridging the gap or gaps and repairing the injured spinal cord or nerve. The procedure may be repeated to extend the area of repair. The severed or otherwise interrupted spinal cord or peripheral nerve is advantageously provided, either internally or alongside, with an insert comprising multiple strands of biodegradable material having magnetic particles oriented along the axis thereof, for focusing and concentrating the external magnetic field in the desired axis.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: October 17, 2000
    Inventor: Alan A. Halpern
  • Patent number: 6127377
    Abstract: The invention concerns novel halogenated derivatives of the vinblastine and vinorelbine family, corresponding to general formula (I) and their therapeutically acceptable salts. The invention also concerns the application of these compounds in therapy and their method of preparation. The invention further concerns a novel method for preparing vinflunine or 20',20'-difluoro-3',4'-dihydrovinorelbine, of formula (a).
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: October 3, 2000
    Assignee: Adir et Compagnie
    Inventors: Alain Duflos, Jacques Fahy, Valerie Thillaye du Boullay, Jean-Marc Barret, Bridget Hill
  • Patent number: 6127369
    Abstract: A compound selected from those of formula (I): ##STR1## wherein: X represents N, C or CH,Y represents N when X represents C or CH, or Y represents C or CH when X represents N,R.sub.1 represents an optionally substituted alkyl,R.sub.2 and R.sub.3, which may be identical or different, represent Z or W, as defined in the description,their isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: October 3, 2000
    Assignee: Adir et Compagnie
    Inventors: Paul Caubere, Gerald Guillaumet, Ivan Rodriguez, Karine Vinter-Pasquier, Catherine Kuehm-Caubere, Stephanie Blanchard, Ghanem Atassi, Alain Pierre, Bruno Pfeiffer, Pierre Renard
  • Patent number: 6127396
    Abstract: The invention relates to a compound of formula (I): ##STR1## wherein: A represents an optionally substituted benzene ring,B represents an imidazoline ring of formula (Ia) or (Ib): ##STR2## X represents CR.sup.6, CR.sup.6 R.sup.7, NR.sup.8, SO or SO.sub.2, or oxygen, nitrogen or sulphur,Y represents a single bond or CH or CH.sub.2,Z represents a carbon atom or CR.sup.4,R.sup.1, R.sup.2, R.sup.3, which may be the same or different, each represent hydrogen or alkyl, it being possible for (R.sup.1 and R.sup.4) or (R.sup.2 and R.sup.4) to form cyclopropane,R.sup.5 represents hydrogen, alkyl or benzyl.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: October 3, 2000
    Assignee: Adir et Compagnie
    Inventors: Alex Cordi, Jean-Michel Lacoste, Mark Millan, Adrian Newman-Tancredi, Alain Gobert
  • Patent number: 6117291
    Abstract: Apparatus for carrying out patch clamp technique utilized in studying the effect of certain materials on ion transfer channels in biological tissue, and more particularly patch clamp apparatus utilizing an autosampler, such as those utilized with HPLC apparatus, to provide high throughput, is disclosed. The invention additionally includes novel microperfusion chamber assemblies capable of utilizing only small amounts of material to be tested and only small amounts of liquid carrier, thereby enabling many tests to be completed in a short period of time. The invention more broadly relates to a novel electrophysiology drug handling and application set up for screening of chemical substances while providing high throughput and requiring only low volume of solutions and samples to be tested. The invention also comprises several novel procedures for utilizing the apparatus of the invention.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: September 12, 2000
    Assignee: NeuroSearch A/S
    Inventors: S.o slashed.ren-Peter Olesen, Palle Christophersen
  • Patent number: 6113928
    Abstract: A stable non-alcoholic cosmetic composition containing 13-trans retinal which is an oil-in-water emulsion in which the fatty phase constituents have a peroxide number no greater than about 5, and in which the fatty phase includes 10-15% by weight of capric/caprylic triglycerides and 0.02-0.5% by weight of the antioxidant BHT, and method of making the same.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: September 5, 2000
    Assignee: Pierre Fabre Dermo-Cosmetique
    Inventors: Laurent Nogueira, Nicole Peyrot
  • Patent number: 6114360
    Abstract: Compounds of formula (I): ##STR1## wherein: R represents hydrogen, alkyl, optionally-substituted amino, or linear or branched (C.sub.1 -C.sub.6)-acyl,R.sub.1 and R.sub.2, which may be identical or different, each represents independently of the other aryl, heteroaryl, or (C.sub.5 -C.sub.7)-cycloalkyl, or one of those groups optionally substituted,A, together with the atoms in common with the pyrrole, represents saturated or unsaturated, monocyclic or bicyclic (C.sub.3 -C.sub.12)-cycloalkyl, or a saturated heterocycle having 5 to 7 ring members and containing one or two nitrogen, or 7-oxabicyclo[2.2.1] heptane, or one of those groups optionally substituted, their isomers, and also addition salts thereof with a pharmaceutically-acceptable acid or base, pharmaceutical compositions thereof, and use thereof as medicaments.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: September 5, 2000
    Assignee: Adir et Compagnie
    Inventors: Guillaume De Nanteuil, Bernard Portevin, Jacqueline Bonnet, Charles Tordjman
  • Patent number: 6113911
    Abstract: A polypeptide useful as an immunogen element and characterized in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and methods for preparing and using the same, are also disclosed.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: September 5, 2000
    Assignee: Pierre Fabre Medicament
    Inventors: Hans Binz, Thien N'Guyen Ngoc, Thierry Baussant, Michel Trudel
  • Patent number: 6107478
    Abstract: A retroviral vector comprising a retrovirus with infectivity for birds and/or mammals in which at least part of the genomic RNA sequences carrying information for the production of viral proteins required in trans for retroviral replication have been replaced by one or more sequences carrying information to be introduced in a target cell chromosome, characterized in that the primer binding site (PBS) has been modified to a sequence that does not allow strong base pairing with the 3' end or other priming sequence in any naturally occurring tRNA. The present application is directed to the tRNA-like primer.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: August 22, 2000
    Inventors: Finn Skou Pedersen, Anders Henrik Lund, Jette Lovmand, Poul J.o slashed.rgensen, Mogens Duch
  • Patent number: 6107345
    Abstract: A compound of formula (I): ##STR1## wherein: Z.sub.1, Z.sub.2, Z.sub.3, Z.sub.4, which may be identical or different, represent a group as defined in the description,X represents oxygen, S(O).sub.p, --(CH.sub.2).sub.n -- or --CH.sub.2 --Y--CH.sub.2 -- wherein p, n and Y are as defined in the description,A represents ##STR2## wherein m, R.sub.1, R.sub.2 and G are as defined in the description, their isomers and addition salts thereof with a pharmaceutically-acceptable acid, and medicinal products containing the same are useful in the treatment of diseases like depression, panic attacks, obsessive compulsive disorders, phobias, impulsive disorders, drug abuse or anxiety.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: August 22, 2000
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Aimee Dessinges, Jean-Christophe Harmange, Mark Millan, Adrian Newman-Tancredi, Mauricette Brocco
  • Patent number: 6099879
    Abstract: A method comprising the step of treating meat and meat products, including fish, poultry, fish products, and poultry products, with a stabilizing amount of rosemary extract or rosemary extract in combination singly or collectively with tocopherols, ascorbic acid, citric acid, or sodium tripolyphosphate, prior to exposure of the meat or meat products to ionizing radiation, enhances the flavor and shelf life thereof. In addition, the active antioxidant ingredients of rosemary extract may be used individually or collectively as a replacement for rosemary extract, these being carnosic acid, carnosol, and rosmarinic acid, which have been found equivalent to or superior to rosemary extract itself for purposes of the present invention when used in the concentrations set forth herein.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: August 8, 2000
    Assignee: Kalamazoo Holdings, Inc.
    Inventor: Paul H. Todd, Jr.
  • Patent number: 6090837
    Abstract: Compounds of formula (I): ##STR1## wherein: m is 0 to 3 inclusive,n is 0 to 3 and 2.ltoreq.m+n.ltoreq.3,p is 1 to 6 inclusive,X represents cyano or --CO--NR.sub.4 R.sub.5, R.sub.4 and R.sub.5 being selected from hydrogen, linear or branched (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, and aryl,R.sub.1 and R.sub.2 each independently represent hydrogen or linear or branched (C.sub.1 -C.sub.6)-alkyl,R.sub.3 represents hydrogen, optionally substituted phenyl, naphthyl or heteroaryl, or aryloxy or arylthio, or aryl or heteroaryl substituted by A'-Cy, A' and Cy being as defined in the description, andmedicinal products containing the same which are useful as D.sub.3 receptor ligands.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: July 18, 2000
    Assignee: Adir et Compagnie
    Inventors: Gilbert Lavielle, Thierry Dubuffet, Patrick Hautefaye, Fran.cedilla.oise Lejeune, Mark Millan
  • Patent number: RE37078
    Abstract: The invention relates to thiophene compounds of formula: wherein: X1, X2, Y1 and Y2, which are identical or different, each represents hydrogen or halogen, (C1-C5)-alkyl or alkoxy, or trifluoromethyl, X1 and Y1, which are identical or different, each represents C1-C5 alkoxy, X2 and Y2 each represents hydrogen, R1 represents hydrogen or (C1-C5)-alkyl, A represents a straight (C1-C5)-hydrocarbon chain of which each carbon atom is optionally mono- or di-substituted by a (C1-C5)-alkyl, and R2 represents hydrogen, (C1-C6)-alkyl, cyclohexyl or benzyl; and their physiologically tolerable salts. The products of the invention may be used as anti-inflammatory agents.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 27, 2001
    Assignee: Adir et Compagnie
    Inventors: Michel Wierzbicki, Frédéric Sauveur, Jacqueline Bonnet, Charles Tordjman